3SOF

Anybody out there following GTCB?

It caught my eye Friday afternoon when it had a nice little pop late in the afternoon.
Rumors are starting about their meeting with the FDA on Jan 9th and was wondering if anyone here has any skinny on them?

"This promotion is well-deserved recognition for the excellent progress Mark has made in advancing the commercialization of our technology, with the most recent achievement being strong data from our First-in-Man study of our drug eluting stent," commented Alan Lindsay.

http://biz.yahoo.com/iw/080107/0345446.html

Does this PR mean we'll being seeing another shortly announcing the good news?

Results of First-In-Man Study With MIVT Low Dose Polymer-Free Drug-Eluting Stent to Be Presented at TCT Conference
Company Presence at TCT to Include One Oral Presentation and Two Posters

ATLANTA, GA, Oct 16, 2007 (MARKET WIRE via COMTEX) -- MIV Therapeutics, Inc. (MIVT:miv therapeutics inc com

MIVT, (FRANKFURT: MIV), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announces that results of the first-in-man safety study with the Company's drug-eluting stent will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2007 conference, to be held October 20-25 at the Washington Convention Center in Washington, D.C.
Principal investigator Alexandre Abizaid, M.D., Ph.D., Chief of Coronary Intervention of Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, will make the presentation titled, "The MIV Polymer-Free Hydroxyapatite-Coated Sirolimus-Eluting Stent: First-in-Man Angiographic and IVUS Follow-Up Results." Dr. Abizaid's presentation will take place on Sunday, October 21 in Room 152A at 3:03 p.m. Eastern time. It is part of a practical workshop titled "First-In-Man Experiences With Drug-Eluting Stents I and Passive and Active Stent Coatings" within the scientific symposia "Innovative Devices and Futuristic Concepts I: Novel Bare Metal and Drug-Eluting Stents."
"We are very pleased the findings of this important first-in-man study will be presented at such a prestigious medical conference. This 15-patient study was conducted very efficiently, and began with the first human implantation of our low dose polymer-free hydroxyapatite-coated drug-eluting stent in May of this year, and each patient was followed for four months," said Dr. Mark Landy, President of MIV Therapeutics. "We are looking forward to the largest-ever presence for MIV Therapeutics at the TCT conference, we believe that acceptance to present at this conference is an important recognition of the significance of our proprietary technology."
The MIV Therapeutics presence at the 2007 TCT conference also will include two posters:
Presented by Greg L. Kaluza, MD, PhD, Cardiovascular Research Foundation:
"Platelet Activation and Adhesion after Exposure to Nanofilm and Microporous Hydroxyapatite Stent Coating: An Ex-Vivo Study of Hydroxyapatite-Coated Stents Deployed in a Continuous Flow-Chamber Model."
Presented by Dr. Dorna Hakimimehr, Scientist MIVT:
"In-Vitro Evaluation of a Novel Dual-Drug Eluting Stent to Target Inflammation and Proliferation Following Stent Implantation."
Dr. Landy added, "Having completed a $12.55 million equity financing in July, we are looking forward to continuing on our path to commercialize a novel drug-eluting stent without the safety issues surrounding current polymer-based drug-eluting stents."

http://www.marketwatch.com/news/story/results-first-in-man-study-mivt-low/story.aspx?guid=%7BD6B81B1A%2D60DB%2D4A27%2D97FD%2D2B80C95C5296%7D&dist=TQP_Mod_pressN

THREE MONTHS ENDED AUGUST 31, 2007 COMPARED TO AUGUST 31, 2006

Revenues. During the three months ended August 31, 2007, revenues from the sale of stents were $301,610 compared to nil for the same quarter of the prior year. Sales were attributed to stents sold by Biosync Scientific in India. There were no comparable sales by the Company for the prior year due the acquisition of Biosync Scientific in February 2007. Cost of goods sold during the quarter ended August 31, 2007 were $258,041 resulting in a gross profit of $43,569. There was no comparable data for the same quarter for the prior year.

http://biz.yahoo.com/e/071015/mivt.ob10-q.html

With TCT starting up this weekend this could be a very good couple of weeks!!!

http://www.tct2007.com/index.php

You gotta love this PR because big pharma is on the prowl and things like this will catch a few eyes:

"...Total revenues for the current quarter increased 286% to $1,625,000 versus $421,000 for the comparable quarter last year. Avid Bioservices, the company's wholly-owned contract manufacturing subsidiary, contributed $1,621,000 in contract manufacturing revenue versus $398,000 recorded in the similar prior year period..."

We're looking mighty cheap here with all this good news lately and should see a POP soon!

This morning should be a good day for Peregrine Pharmaceuticals with this UT Southwestern Medical Center news release:

http://www.utsouthwestern.edu/utsw/cda/dept353744/files/409646.html

Hopefully this is what they needed to get them out of the basement. Looks like all the insiders have been loading up as well:

http://www.insidercow.com/history/company.jsp?company=pphm

MIV Therapeutics Announces Renowned Researcher to Detail Milestone Pre-Clinical Results at Prominent International Conference EuroPCR 2007

Tuesday May 22, 4:01 pm ET 

ATLANTA--MIV Therapeutics (OTCBB:MIVT - News; FWB:MIV), a leading developer of next generation biocompatible coatings and advanced drug delivery systems for Cardiovascular stents and other implantable medical devices, is pleased to announce that results from an animal trial comparing its proprietary polymer free Hydroxyapatite-coated drug-eluting cardiovascular stent to J&J's Cypher Stent will be presented at this weeks EuroPCR 2007 conference in Barcelona, Spain.

Dr Willem J. van der Giesen, MD, PhD from the Erasmus University Medical Center will make a presentation on next generation drug eluting stents, in which he will discuss the results of the 4 week porcine study, performed by the Department of Cardiology, Thoraxcenter, Erasmus University Medical Center in the Netherlands, an independent research organization.

The study indicated that three variations of MIVT's Hydroxyapatite-based Drug-Eluting stents were at least as effective as, and in some cases, better than one of the worlds leading drug-eluting cardiovascular stents produced by Johnson & Johnson (Cypher(TM)). These results provided the necessary data to advance the technology to human studies.

Hydroxyapatite, unlike polymer coatings, is naturally derived and found in such hard tissues and bioceramic materials as human bone and teeth. Research has indicated that MIVT's HAp coatings do not trigger the various adverse and inflammatory reactions that are often associated with implantation of polymer-coated stents and other foreign substances.

HAp coatings are also expected to reduce the risk of thrombogenic (blood clotting) events attributable in some instances to polymer-coated stents. Some of the most recent information presented at various conferences estimated that thrombogenicity was identified in at least 20,000 cases of implanted drug-eluting stents to-date, resulting in approximately 8,000 premature deaths.

EuroPCR is a major European event based on the exchanged of scientific information and education for interventional cardiologists.

http://biz.yahoo.com/bw/070522/20070522006185.html?.v=1

It looks like it's time to pick up some VICL. Looking for some follow through today and a positive PR on the HIV results next week.

http://www.americanbulls.com/StockPage.asp?CompanyTicker=VICL&MarketTicker=NASD&TYP=S

"...As always, the projections made in the conference call were based on our best available information at the time. While specific dates and venues for release of the HIV data were not provided, we believe the data are available internally at the NIH, and could be presented at any time.

In the past, the NIH has presented data at the Keystone symposia on HIV. The Keystone web site shows that Dr. Gary Nabel of the Vaccine Research Center is scheduled to present at the Keystone symposia next Tuesday, March 27, but the specific topics to be covered are not disclosed. We will be watching with interest."

So, it looks like all eyes will be watching the newswires & Keystone next week concerning the results...

http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_V/threadview?m=tm&bn=19346&tid=25691&mid=25697&tof=2&frt=2

Are they finally turning the corner?

Leading Global Pharmaceutical Customer Selects BackWeb's Offline Web Technology for its Global Workforce

"...We're pleased to build on our partnership with existing customers," said Bill Heye, CEO of BackWeb. "We look forward to helping them achieve year over year productivity increases by taking their business web applications to the next level of usability and relevance for their employees. Our expanded relationship with this pharmaceutical customer is another exciting example of how BackWeb's offerings are increasingly being recognized as a leader in delivering the business web 'unplugged' and providing real value to our global customers."

With the enterprise license, the customer will also apply BackWeb's unique technology within its global architecture to optimize the delivery of other critical information, further maximizing the return on their investment. In doing so, the customer can capitalize on the investments it has already made while delivering anytime, anywhere productivity to its mobile, global workforce..."

http://biz.yahoo.com/bw/070315/20070315005396.html?.v=1

BackWeb Reports Q4 2006 Results Reflecting a Substantial Reduction in Sequential Quarterly Net Loss

"...As a result of lower than expected total net expenses, in Q4 2006 BackWeb reported a lower than anticipated net loss of $204,000, or break-even on a per share basis, compared to a net loss of $1.6 million, or ($0.04) per share, in Q3 2006, and a net loss of $301,000, or ($0.01) per share, in Q4 2005....

...Ken Holmes, BackWeb's CFO, commented, "We're pleased that our Q4 2006 net loss came in better than the preliminary results we provided. This was principally due to a few favorable adjustments that resulted from our year-end audit and lower than expected operating expenses in the quarter. Given our cost reductions and spending discipline, as well as the $4.5 million in cash and investments on our balance sheet as of December 31, 2006, we believe BackWeb is sufficiently capitalized to execute on our business plan throughout 2007 and beyond..."

http://biz.yahoo.com/bw/070302/20070302005103.html?.v=1

I came across this company this weekend and liked everything I read about them.

"..."We feel very confident that fiscal year 2007 will be the most exciting and rewarding in MIVT's history," said Dr. Mark Landy. "We will leverage these funds to promote the various strategic initiatives that are currently positioning MIVT to capitalize on the growing international markets for stent technology..."

http://biz.yahoo.com/bw/070108/20070108005064.html?.v=1

If somebody like JNJ or BSX picked them up this could explode which is why I'm going to buy some at the open!

eFoodSafety.com Announces Cinnergen(TM) Now Distributed Through Cardinal Health

"...Patricia Gruden, President and CEO of eFoodSafety.com, Inc., stated, "We are very pleased to add Cardinal Health to our growing list of Cinnergen(TM) distributors. Cardinal Health is a premiere global healthcare company with a commitment to customer service and operational excellence..."


http://biz.yahoo.com/bw/070118/20070118005221.html?.v=1

Cinnergen is sounding more and more interesting:

Good Morning,
My husband was diagnosed with type II diabetes four years ago. He has been using the Cinnergen product for about 1 maybe 1 1/2 years. There is a marked improvement in his numbers. In the recent press release there is information regarding libido, beleive it! When he has slowed down in taking this product, because of the cost to me, I have noticed as his wife would notice such things. I then re-encourage him to not worry if there is such an improvment.
He now takes it faithfully and I take it to for the cholesterol lowering properties.
Spread The Word.

http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_E/threadview?m=tm&bn=49908&tid=52&mid=54&tof=1&rt=2&frt=2&off=1

More news out on Cinnergen(TM) this morning!

http://biz.yahoo.com/bw/070116/20070116005585.html?.v=1

eFoodSafety.com, Inc. Subsidiary Knock-Out Technologies, Ltd. Developing Joint Licensing Agreement with United States Department of Agriculture (USDA) for Patent-Pending OraPhyte Product
Wednesday January 10, 4:15 pm ET 

OraPhyte is Designed to Combat Plant-Parasitic Nematodes That Cause an Annual Estimated Crop Loss of $100 Billion Globally


http://biz.yahoo.com/bw/070110/20070110006024.html?.v=1